Drug Approval | January 16, 2026
Zydus receives final approval from USFDA for Eltrombopag Tablets
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
Experts caution that realizing AI’s potential requires careful management and risk mitigation
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
